BR112019021868A2 - Sal de um composto derivado de aminopiridina, forma cristalina do mesmo, e processo para a preparação do mesmo - Google Patents
Sal de um composto derivado de aminopiridina, forma cristalina do mesmo, e processo para a preparação do mesmo Download PDFInfo
- Publication number
- BR112019021868A2 BR112019021868A2 BR112019021868-8A BR112019021868A BR112019021868A2 BR 112019021868 A2 BR112019021868 A2 BR 112019021868A2 BR 112019021868 A BR112019021868 A BR 112019021868A BR 112019021868 A2 BR112019021868 A2 BR 112019021868A2
- Authority
- BR
- Brazil
- Prior art keywords
- same
- crystalline form
- preparation
- salt
- aminopyridine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 150000003927 aminopyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
- C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
a presente invenção se refere a sal de mesilato inovador de n-(5-(4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidina-2-ilamino)-4-metóxi-2-morfolinofenil)acrilamida, uma forma cristalina inovadora do mesmo, e um processo para a preparação do mesmo. mais especificamente, a presente invenção se refere a um sal de mesilato de n-(5-(4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidina-2-ilamino)-4-metóxi-2-morfolinofenil)acrilamida, que é excelente em termos de estabilidade, solubilidade e biodisponibilidade, quando ele é administrado não apenas sozinho, mas também em combinação com outros fármacos e que apresenta uma alta pureza, um forma cristalina do mesmo, e um processo para a preparação do mesmo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170051687 | 2017-04-21 | ||
KR10-2017-0051687 | 2017-04-21 | ||
PCT/KR2018/004473 WO2018194356A1 (en) | 2017-04-21 | 2018-04-18 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019021868A2 true BR112019021868A2 (pt) | 2020-05-26 |
Family
ID=63857137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019021868-8A BR112019021868A2 (pt) | 2017-04-21 | 2018-04-18 | Sal de um composto derivado de aminopiridina, forma cristalina do mesmo, e processo para a preparação do mesmo |
Country Status (23)
Country | Link |
---|---|
US (2) | US11453656B2 (pt) |
EP (1) | EP3612529A4 (pt) |
JP (2) | JP7126514B2 (pt) |
KR (2) | KR102629654B1 (pt) |
CN (1) | CN110869367B (pt) |
AR (1) | AR111469A1 (pt) |
AU (2) | AU2018256227B2 (pt) |
BR (1) | BR112019021868A2 (pt) |
CA (1) | CA3059543A1 (pt) |
CO (1) | CO2019011578A2 (pt) |
EA (1) | EA201992501A1 (pt) |
IL (2) | IL270018B (pt) |
MA (1) | MA49696A (pt) |
MX (1) | MX2022006357A (pt) |
MY (1) | MY201919A (pt) |
NZ (1) | NZ758443A (pt) |
PH (1) | PH12019502370A1 (pt) |
SA (1) | SA519410342B1 (pt) |
SG (1) | SG11201909615YA (pt) |
TW (1) | TWI776882B (pt) |
UA (1) | UA124364C2 (pt) |
WO (1) | WO2018194356A1 (pt) |
ZA (1) | ZA201907687B (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
CN111349084B (zh) * | 2018-12-21 | 2022-11-25 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的氨基嘧啶类化合物 |
SG11202108311RA (en) | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
JOP20210304A1 (ar) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث |
US11850248B2 (en) * | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
CN113840601A (zh) * | 2019-05-14 | 2021-12-24 | 詹森生物科技公司 | 使用双特异性抗EGFR/c-Met抗体和第三代EGFR酪氨酸激酶抑制剂的组合疗法 |
TW202207940A (zh) * | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
EP4349835A1 (en) | 2021-06-01 | 2024-04-10 | Hangzhou Solipharma Co., Ltd. | Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101337933B (zh) | 2003-12-25 | 2011-03-02 | 卫材R&D管理有限公司 | 喹啉羧酰胺的甲磺酸盐的结晶(a)及其制备方法 |
CA2555804C (en) | 2004-02-11 | 2012-06-26 | Natco Pharma Limited | Polymorphic form of imatinib mesylate and a process for its preparation |
SG10201510696RA (en) * | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
CZ2009570A3 (cs) | 2009-08-26 | 2011-03-09 | Zentiva, K. S. | Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem |
CA2780892C (en) | 2009-11-13 | 2017-02-14 | Genosco | Kinase inhibitors |
US9006448B2 (en) * | 2010-12-06 | 2015-04-14 | Msn Laboratories Private Limited | Process for the preparation of benzimidazole derivatives and its salts |
WO2013014448A1 (en) | 2011-07-27 | 2013-01-31 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
WO2015003571A1 (zh) | 2013-07-08 | 2015-01-15 | 杭州普晒医药科技有限公司 | 达拉菲尼甲磺酸盐的新晶型及其制备方法 |
JP6468611B2 (ja) | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ, インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
BR112017007769B1 (pt) * | 2014-10-13 | 2023-10-10 | Yuhan Corporation | Compostos derivados de aminopirimidina, composição farmacêutica que compreende os ditos compostos e uso terapêutico dos mesmos |
CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
-
2018
- 2018-04-13 AR ARP180100945A patent/AR111469A1/es unknown
- 2018-04-18 SG SG11201909615Y patent/SG11201909615YA/en unknown
- 2018-04-18 KR KR1020180044850A patent/KR102629654B1/ko active IP Right Grant
- 2018-04-18 CA CA3059543A patent/CA3059543A1/en active Pending
- 2018-04-18 MY MYPI2019006145A patent/MY201919A/en unknown
- 2018-04-18 IL IL270018A patent/IL270018B/en unknown
- 2018-04-18 IL IL294666A patent/IL294666B2/en unknown
- 2018-04-18 US US16/605,944 patent/US11453656B2/en active Active
- 2018-04-18 NZ NZ758443A patent/NZ758443A/en unknown
- 2018-04-18 EA EA201992501A patent/EA201992501A1/ru unknown
- 2018-04-18 TW TW107113234A patent/TWI776882B/zh active
- 2018-04-18 UA UAA201911263A patent/UA124364C2/uk unknown
- 2018-04-18 WO PCT/KR2018/004473 patent/WO2018194356A1/en active Application Filing
- 2018-04-18 BR BR112019021868-8A patent/BR112019021868A2/pt active Search and Examination
- 2018-04-18 EP EP18787260.1A patent/EP3612529A4/en active Pending
- 2018-04-18 CN CN201880026342.7A patent/CN110869367B/zh active Active
- 2018-04-18 MA MA049696A patent/MA49696A/fr unknown
- 2018-04-18 JP JP2019556610A patent/JP7126514B2/ja active Active
- 2018-04-18 AU AU2018256227A patent/AU2018256227B2/en active Active
-
2019
- 2019-10-18 CO CONC2019/0011578A patent/CO2019011578A2/es unknown
- 2019-10-18 PH PH12019502370A patent/PH12019502370A1/en unknown
- 2019-10-20 SA SA519410342A patent/SA519410342B1/ar unknown
- 2019-10-21 MX MX2022006357A patent/MX2022006357A/es unknown
- 2019-11-20 ZA ZA2019/07687A patent/ZA201907687B/en unknown
-
2022
- 2022-03-17 US US17/697,655 patent/US11981659B2/en active Active
- 2022-05-23 AU AU2022203486A patent/AU2022203486A1/en active Pending
- 2022-08-16 JP JP2022129468A patent/JP7390444B2/ja active Active
-
2023
- 2023-12-18 KR KR1020230184208A patent/KR20230175161A/ko not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019021868A2 (pt) | Sal de um composto derivado de aminopiridina, forma cristalina do mesmo, e processo para a preparação do mesmo | |
PH12018550120A1 (en) | Steroid derivative fxr agonist | |
EA201892007A1 (ru) | 3-дезоксипроизводное и фармацевтические композиции на его основе | |
EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
EA201591531A1 (ru) | Ингибиторы аргининметилтрансферазы и их применения | |
BR112016010383A2 (pt) | compostos de pyy seletivos e usos dos mesmos | |
EA201501122A1 (ru) | Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4) | |
EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
BR112013017302A2 (pt) | formulações de imunossupressor | |
CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
EA201690888A1 (ru) | Новые гетероциклические соединения | |
MX2016005142A (es) | Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos. | |
CY1122468T1 (el) | Κρυσταλλικη μορφη διθειικου αναστολεα κινασης jak και μια μεθοδος παρασκευης αυτου | |
EA201692298A1 (ru) | Производные карбоксамидов | |
EA201891682A1 (ru) | Производное азациклического амида, способ его получения и фармацевтическое применение | |
EA201890684A1 (ru) | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 | |
EA201591649A1 (ru) | Составы с органическими соединениями | |
WO2015002755A3 (en) | Compounds for the treatment of malaria | |
JOP20170197B1 (ar) | الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول | |
BR112016009214A8 (pt) | uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica | |
BR112021017353A2 (pt) | Forma de composto com biodisponibilidade aprimorada e formulações da mesma | |
MX2017008072A (es) | Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa. | |
WO2016165205A8 (zh) | 一种新型的bcr-abl激酶抑制剂 | |
MX2016006904A (es) | Derivados de amida como agonistas del receptor 119 acoplado a proteina g (gpr119). | |
NZ630795A (en) | Crystalline form of vsn16 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |